Riskpilot← Back to searchSign inGet full accessNORMED INVEST AS
ASActiveOrg 927465825Paul Figenschous Veg 5A, 9009 TromsøOther human health activities n.e.c. · NACE 8699Est. 20211 employees
Revenue 2024
NOK 2M
-27% vs 2023
EBITDA margin
5.3%
-90% vs 2023
Equity ratio
89.9%
Financial strength
Net profit 2024
NOK 137K
-83% vs 2023
| Revenue | NOK 2M | -27% |
| EBITDA | NOK 103K | -90% |
| Net profit | NOK 137K | -83% |
| Total assets | NOK 2,3M | -11% |
| Equity | NOK 2,1M | -6% |
| Employees | 1 | — |
Legal name
NORMED INVEST AS
Org number
927465825
Legal form
Aksjeselskap
NACE code
8699 · Other human health activities n.e.c.
Founded
4. oktober 2021
Share capital
NOK 30 000
Employees
1 (FTE)
VAT registered
No
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
To styremedlemmer i fellesskap. Styrets leder og ett styremedlem i fellesskap.
Company purpose
Helserelaterte tjenester og undervisning, å eie og leie ut eiendom, investering i aksjer og andre investeringer når det finnes tjenlig for selskapet.
Address
Paul Figenschous Veg 5A, 9009 Tromsø
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|
| Revenue | 1 469 | 2 536 | 2 656 | 1 952 |
| Staff expenses | −12 | −1 105 | −952 | −1 254 |
| EBITDA | 1 274 | 765 | 985 | 103 |
| Depreciation & amort. | −1 | −9 | −10 | −10 |
| EBIT | 1 272 | 756 | 975 | 93 |
| Net financials | 0 | 23 | 80 | 90 |
| Profit before tax | 1 272 | 779 | 1 055 | 182 |
| Tax | 279 | 172 | 233 | 45 |
| Net profit | 994 | 608 | 822 | 137 |
| Item | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|
| Total assets | 1 297 | 1 983 | 2 616 | 2 330 |
| Equity | 1 018 | 1 626 | 2 218 | 2 095 |
| Long-term debt | 5 | 3 | 3 | 2 |
| Short-term debt | 274 | 354 | 395 | 233 |
| Total debt | 279 | 357 | 398 | 236 |
EBITDA margin
5.3%
This company
15.8%
Market median
-66% vs market
20212024
Equity ratio
89.9%
This company
38.2%
Market median
+135% vs market
20212024
Return on equity
6.5%
This company
18.4%
Market median
-65% vs market
20212024
Net profit margin
7.0%
This company
8.1%
Market median
-14% vs market
20212024
Asset turnover
0.84×
This company
1.12×
Market median
+25% vs market
20212024
Debt / equity
0.11×
This company
0.62×
Market median
+82% vs market
20212024
- Annual report 2024Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-09-07 – 2021-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
KE Chief Executive Officer | Chief Executive Officer | 2021 |
| Name | Role | Member since |
|---|---|---|
| Current (4) | ||
| Board of Directors | 2023 | |
| Chairman | 2023 | |
| Board of Directors | 2023 | |
| Board of Directors | 2023 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of NORMED INVEST AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Kristine Eline Jørgensen | Chief Executive Officer | 0 companies |
| Benjamin Nikolai Tylden | Board of Directors | 0 companies |
| Garth Daryl Tylden | Chairman | 0 companies |
| Eline Sol Garthsdatter Tylden | Board of Directors | 0 companies |
| Leonard Tylden | Board of Directors | 0 companies |